Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond

Ricardo A. M. Serafim,Matthias Gehringer,Chiara Borsari

DOI: https://doi.org/10.3390/ph17020206

IF: 4.6

2024-02-06

Pharmaceuticals

Abstract:Covalent inhibitors have experienced a revival in medicinal chemistry and chemical biology in recent decades [...]

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

Covalent Inhibition in Drug Discovery

Avick Kumar Ghosh,Indranil Samanta,Anushree Mondal,Wenshe Ray Liu

DOI: https://doi.org/10.1002/cmdc.201900107

IF: 3.54

2019-03-26

ChemMedChem

Abstract:Although covalent inhibitors have been used as therapeutics for more than a century, there has been general resistance in the pharmaceutical industry against their further development due to safety concerns. This inclination has recently been reverted after the development of a wide variety of covalent inhibitors to address human health conditions along with the US Food and Drug Administration (FDA) approval of several covalent therapeutics for use in humans. Along with this exciting resurrection of an old drug discovery concept, this review surveys enzymes that can be targeted by covalent inhibitors for the treatment of human diseases. We focus on protein kinases, RAS proteins, and a few other enzymes that have been studied extensively as targets for covalent inhibition, with the aim to address challenges in designing effective covalent drugs and to provide suggestions in the area that have yet to be explored.

pharmacology & pharmacy,chemistry, medicinal
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Laura Hillebrand,Xiaojun Julia Liang,Ricardo A M Serafim,Matthias Gehringer

DOI: https://doi.org/10.1021/acs.jmedchem.3c01825

IF: 8.039

2024-05-08

Journal of Medicinal Chemistry

Abstract:Covalent inhibitors and other types of covalent modalities have seen a revival in the past two decades, with a variety of new targeted covalent drugs having been approved in recent years. A key feature of such molecules is an intrinsically reactive group, typically a weak electrophile, which enables the irreversible or reversible formation of a covalent bond with a specific amino acid of the target protein. This reactive group, often called the "warhead", is a critical determinant of the...

chemistry, medicinal
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Jesang Lee,Seung Bum Park

DOI: https://doi.org/10.3390/ph15121478

2022-11-27

Abstract:Recently, small-molecule covalent inhibitors have been accepted as a practical tool for targeting previously "undruggable" proteins. The high target selectivity of modern covalent inhibitors is now alleviating toxicity concerns regarding the covalent modifications of proteins. However, despite the tremendous clinical success of current covalent inhibitors, there are still unmet medical needs that covalent inhibitors have not yet addressed. This review categorized representative covalent inhibitors based on their mechanism of covalent inhibition: conventional covalent inhibitors, targeted covalent inhibitors (TCIs), and expanded TCIs. By reviewing both Food and Drug Administration (FDA)-approved drugs and drug candidates from recent literature, we provide insight into the future direction of covalent inhibitor development.
Recent applications of covalent chemistries in protein-protein interaction inhibitors

Alexandria M Chan,Christopher C Goodis,Elie G Pommier,Steven Fletcher

DOI: https://doi.org/10.1039/d2md00112h

2022-06-03

Abstract:Protein-protein interactions (PPIs) are large, often featureless domains whose modulations by small-molecules are challenging. Whilst there are some notable successes, such as the BCL-2 inhibitor venetoclax, the requirement for larger ligands to achieve the desired level of potency and selectivity may result in poor "drug-like" properties. Covalent chemistry is presently enjoying a renaissance. In particular, targeted covalent inhibition (TCI), in which a weakly electrophilic "warhead" is installed onto a protein ligand scaffold, is a powerful strategy to develop potent inhibitors of PPIs that are smaller/more drug-like yet have enhanced affinities by virtue of the reinforcing effect on the existing non-covalent interactions by the resulting protein-ligand covalent bond. Furthermore, the covalent bond delivers sustained inhibition, which may translate into significantly reduced therapeutic dosing. Herein, we discuss recent applications of a spectrum of TCIs, as well as covalent screening strategies, in the discovery of more effective inhibitors of PPIs using the HDM2 and BCL-2 protein families as case studies.
Advances in covalent drug discovery

Lydia Boike,Nathaniel J. Henning,Daniel K. Nomura

DOI: https://doi.org/10.1038/s41573-022-00542-z

IF: 112.288

2022-08-26

Nature Reviews Drug Discovery

Abstract:Covalent drugs have been used to treat diseases for more than a century, but tools that facilitate the rational design of covalent drugs have emerged more recently. The purposeful addition of reactive functional groups to existing ligands can enable potent and selective inhibition of target proteins, as demonstrated by the covalent epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK) inhibitors used to treat various cancers. Moreover, the identification of covalent ligands through 'electrophile-first' approaches has also led to the discovery of covalent drugs, such as covalent inhibitors for KRAS(G12C) and SARS-CoV-2 main protease. In particular, the discovery of KRAS(G12C) inhibitors validates the use of covalent screening technologies, which have become more powerful and widespread over the past decade. Chemoproteomics platforms have emerged to complement covalent ligand screening and assist in ligand discovery, selectivity profiling and target identification. This Review showcases covalent drug discovery milestones with emphasis on the lessons learned from these programmes and how an evolving toolbox of covalent drug discovery techniques facilitates success in this field.

pharmacology & pharmacy,biotechnology & applied microbiology
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

Qiongqiong Zhou,Haitao Chen,DaSheng Wang,Robert Bird,Leilani Lotti Diaz,Kavita Iyer,Gary Gustafson,Junko Kato-Weinstein

DOI: https://doi.org/10.26434/chemrxiv-2023-wf79n-v2

2023-11-06

Abstract:CCovalent inhibitors are being used more frequently in drug discovery and is expected to revolutionize how enzyme inhibitors and receptor modulators are created in the future. More than 30 covalent therapies have been approved by the US FDA as a result of this approach, which has produced a wide spectrum of effective treatments. Covalent inhibitors have also made it possible to target previously neglected targets, demonstrating that covalent inhibition has a tremendous opportunity to cure human diseases. We analyzed the CAS Content Collection to examine the publishing trends of covalent inhibitors with various types of warheads and their target proteins for developing a landscape view of the research effort in this area. We identify potential substructures for specific protein targets by assessing the frequencies of specific warhead structures in covalent inhibitors. In addition, a comprehensive database of warheaded compounds and the corresponding protein targets has been collected, which may be useful for analysis of structure-activity relationships. Our work provides an overview of covalent inhibitor research and demonstrates how the power of the analysis of large data sets can accelerate research and development.

Chemistry
Applications of covalent chemistry in targeted protein degradation

Dong Lu,Xin Yu,Hanfeng Lin,Ran Cheng,Erika Y Monroy,Xiaoli Qi,Meng C Wang,Jin Wang

DOI: https://doi.org/10.1039/d2cs00362g

2022-11-14

Abstract:Proteolysis-targeting chimeras (PROTACs) and targeted covalent inhibitors (TCIs) are currently two exciting strategies in the fields of chemical biology and drug discovery. Extensive research in these two fields has been conducted, and significant progress in these fields has resulted in many clinical candidates, some of which have been approved by FDA. Recently, a novel concept termed covalent PROTACs that combine these two strategies has emerged and gained an increasing interest in the past several years. Herein, we briefly review and highlight the mechanism and advantages of TCIs and PROTACs, respectively, and the recent development of covalent PROTACs using irreversible and reversible covalent chemistry.
Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action

Disha Patel,Zil E Huma,Dustin Duncan

DOI: https://doi.org/10.1021/acschembio.3c00805

IF: 4.634

2024-04-03

ACS Chemical Biology

Abstract:Covalent inhibition has seen a resurgence in the last several years. Although long-plagued by concerns of off-target effects due to nonspecific reactions leading to covalent adducts, there has been success in developing covalent inhibitors, especially within the field of anticancer therapy. Covalent inhibitors can have an advantage over noncovalent inhibitors since the formation of a covalent adduct may serve as an additional mode of selectivity due to the intrinsic reactivity of the target...

biochemistry & molecular biology
Advanced technologies for screening and identifying covalent inhibitors

Yaolin Guo,Wen shuai,Aiping Tong,Yuxi Wang

DOI: https://doi.org/10.1016/j.trac.2024.117833

IF: 14.908

2024-06-27

TrAC Trends in Analytical Chemistry

Abstract:Covalent inhibitors, forming reversible or irreversible covalent bonds with nucleophilic groups in target protein active sites, effectively inhibit protein function for therapeutic purposes. They can also be used for target validation, biomarker identification, and as chemical probes. Boasting high bioefficiency, low drug resistance, and minimal off-target effects, covalent inhibitors possess significant application potential within the small molecule drug market. Their discovery usually involves rational drug design. Understanding screening and identification tools for covalent inhibitors aids in selecting suitable and efficient development methods. This review encompasses screening platforms, target-ligand covalent binding, and selective analysis tools used in covalent inhibitor development. It focuses on discovery strategies such as computer-aided drug design, library screening, and classic techniques for binding determination and selectivity. Examples highlight the advantages and limitations of screening platforms, offering insights for covalent inhibitor discovery and advancing drug development.

chemistry, analytical
CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors

Hongyan Du,Junbo Gao,Gaoqi Weng,Junjie Ding,Xin Chai,Jinping Pang,Yu Kang,Dan Li,Dongsheng Cao,Tingjun Hou

DOI: https://doi.org/10.1093/nar/gkaa876

IF: 14.9

2020-10-17

Nucleic Acids Research

Abstract:Abstract Inhibitors that form covalent bonds with their targets have traditionally been considered highly adventurous due to their potential off-target effects and toxicity concerns. However, with the clinical validation and approval of many covalent inhibitors during the past decade, design and discovery of novel covalent inhibitors have attracted increasing attention. A large amount of scattered experimental data for covalent inhibitors have been reported, but a resource by integrating the experimental information for covalent inhibitor discovery is still lacking. In this study, we presented Covalent Inhibitor Database (CovalentInDB), the largest online database that provides the structural information and experimental data for covalent inhibitors. CovalentInDB contains 4511 covalent inhibitors (including 68 approved drugs) with 57 different reactive warheads for 280 protein targets. The crystal structures of some of the proteins bound with a covalent inhibitor are provided to visualize the protein–ligand interactions around the binding site. Each covalent inhibitor is annotated with the structure, warhead, experimental bioactivity, physicochemical properties, etc. Moreover, CovalentInDB provides the covalent reaction mechanism and the corresponding experimental verification methods for each inhibitor towards its target. High-quality datasets are downloadable for users to evaluate and develop computational methods for covalent drug design. CovalentInDB is freely accessible at http://cadd.zju.edu.cn/cidb/.

biochemistry & molecular biology
Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Yangcheng Ai,Zichao Yang,Zilong Yang,Shanhe Wan,Chunhui Huang,Chuan Huang,Mingxia Li,Zhonghuang Li,Jiajie Zhang,Tingting Zhang

DOI: https://doi.org/10.1021/acs.jcim.2c00458

IF: 6.162

2023-01-01

Journal of Chemical Information and Modeling

Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.
CovalentInDB 2.0: an Updated Comprehensive Database for Structure-Based and Ligand-Based Covalent Inhibitor Design and Screening.

Hongyan Du,Xujun Zhang,Zhenxing Wu,Odin Zhang,Shukai Gu,Mingyang Wang,Feng Zhu,Dan Li,Tingjun Hou,Peichen Pan

DOI: https://doi.org/10.1093/nar/gkae946

IF: 14.9

2024-01-01

Nucleic Acids Research

Abstract:The rational design of targeted covalent inhibitors (TCIs) has emerged as a powerful strategy in drug discovery, known for its ability to achieve strong binding affinity and prolonged target engagement. However, the development of covalent drugs is often challenged by the need to optimize both covalent warhead and non-covalent interactions, alongside the limitations of existing compound libraries. To address these challenges, we present CovalentInDB 2.0, an updated online database designed to support covalent drug discovery. This updated version includes 8303 inhibitors and 368 targets, supplemented by 3445 newly added cocrystal structures, providing detailed analyses of non-covalent interactions. Furthermore, we have employed an AI-based model to profile the ligandability of 144 864 cysteines across the human proteome. CovalentInDB 2.0 also features the largest covalent virtual screening library with 2 030 192 commercially available compounds and a natural product library with 105 901 molecules, crucial for covalent drug screening and discovery. To enhance the utility of these compounds, we performed structural similarity analysis and drug-likeness predictions. Additionally, a new user data upload feature enables efficient data contribution and continuous updates. CovalentInDB 2.0 is freely accessible at http://cadd.zju.edu.cn/cidb/. Graphical Abstract
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Yi Zhang,Deqin Rong,Bingbing Li,Yuanxiang Wang

DOI: https://doi.org/10.1021/acs.jmedchem.0c02055

IF: 8.039

2021-02-18

Journal of Medicinal Chemistry

Abstract:Epigenetic regulation of gene expression plays a critical role in various physiological processes, and epigenetic dysregulation is implicated in a number of diseases, prominently including cancer. Epigenetic regulators have been validated as potential therapeutic targets, and significant progress has been made in the discovery and development of epigenetic-based inhibitors. However, successful epigenetic drug discovery is still facing challenges, including moderate selectivity, limited efficacy, and acquired drug resistance. Inspired by the advantages of covalent small-molecule inhibitors, targeted covalent inhibition has attracted increasing interest in epigenetic drug discovery. In this review, we comprehensively summarize the structure-based design and characterization of covalent inhibitors targeting epigenetic writers, readers, and erasers and highlight their potential benefits in enhancing selectivity across the enzyme family and improving in vivo efficacy. We also discuss the challenges and opportunities of covalent small-molecule inhibitors and hope to shed light on future epigenetic drug discovery.This article has not yet been cited by other publications.

chemistry, medicinal
Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery

Nazmul Hasan,Manisha Ray,Arjun Saha,Md Nazmul Hasan

DOI: https://doi.org/10.1021/acs.jpcb.3c04710

IF: 3.466

2023-11-04

The Journal of Physical Chemistry B

Abstract:Covalent drug discovery has been a challenging research area given the struggle of finding a sweet balance between selectivity and reactivity for these drugs, the lack of which often leads to off-target activities and hence undesirable side effects. However, there has been a resurgence in covalent drug design following the success of several covalent drugs such as boceprevir (2011), ibrutinib (2013), neratinib (2017), dacomitinib (2018), zanubrutinib (2019), and many others. Design of covalent...

chemistry, physical
Covalent Inhibitors: To Infinity and Beyond

Yasir S. Raouf

DOI: https://doi.org/10.1021/acs.jmedchem.4c01308

IF: 8.039

2024-06-26

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Jun 24. doi: 10.1021/acs.jmedchem.4c01308. Online ahead of print. NO

chemistry, medicinal
Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Tingting Zhang

DOI: https://doi.org/10.1021/acs.jcim.2c00458

2023-01-01

Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.
Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

Luhong Wang,Jingyuan Zhao,Yao,Changyuan Wang,Jianbin Zhang,Xiaohong Shu,Xiuli Sun,Yanxia Li,Kexin Liu,Hong Yuan,Xiaodong Ma

DOI: https://doi.org/10.1016/j.ejmech.2017.09.024

IF: 7.088

2017-01-01

European Journal of Medicinal Chemistry

Abstract:Cancer remains the most serious disease that threatens human health. Molecularly targeted cancer therapies, specifically small-molecule protein kinase inhibitors, form an important part of cancer therapy. Targeted covalent modification represents a proven approach to drug discovery with the recent FDA approvals of afatanib, ibrutinib, and osimertinib agents, which were designed to undergo an irreversible hetero-Michael addition reaction with a unique cysteine residue of a specific protein. Covalent inhibitors possess numerous advantages, including increased biochemical efficacy, longer duration of action, the high potential for improved therapeutic index due to lower effective dose, and the potential to inhibit certain drug resistance mechanisms. In this regard, the novel targeted anticancer agents whose activity is presumably dependent upon a hetero-Michael addition reaction with thiols are summarized in this article.
Covalent inhibitors meet epigenetics: New opportunities

Qiang Feng,Luoting Yu,Lu Li,Qiangsheng Zhang

DOI: https://doi.org/10.1016/j.ejmech.2024.116951

2024-12-15

Abstract:Epigenetic intervention has become an important therapeutic strategy for a variety of diseases, such as cancer. Although a small number of epigenetic drugs have been marketed, most of these inhibitors are limited by their poor efficacy, dose-dependent toxicity, poor selectivity, and drug resistance. The development of covalent inhibitors has progressed from questioning to resurgence. Its slow dissociation is expected to inject new vitality into epigenetic drugs. In this review, more than 40 covalent inhibitors of 29 epigenetic targets were collated, focusing on their design strategies, reaction mechanisms, covalent warheads and targeted amino acids, and covalent verification methods. Furthermore, this review presented new opportunities based on the current development of covalent inhibitors targeting epigenetic regulators. It is believed that epigenetic covalent inhibitors will lead to more breakthroughs.
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs

Jan Felix Scholtes,Cristobal Alhambra,Philip A. Carpino

DOI: https://doi.org/10.1080/13543776.2024.2400175

2024-09-12

Expert Opinion on Therapeutic Patents

Abstract:Introduction Covalent drugs contain electrophilic groups that can react with nucleophilic amino acids located in the active sites of proteins, particularly enzymes. Recently, there has been considerable interest in using covalent drugs to target non-catalytic amino acids in proteins to modulate difficult targets (i.e. targeted covalent inhibitors). Covalent compounds contain a wide variety of covalent reacting groups (CRGs), but only a few of these CRGs are present in FDA-approved covalent drugs.

pharmacology & pharmacy,chemistry, medicinal
Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

Jin Li,Christopher W. Murray,Bohdan Waszkowycz,Stephen Young

DOI: https://doi.org/10.1016/s1359-6446(97)01138-0

IF: 8.369

1998-01-01

Drug Discovery Today

Abstract:A powerful new approach emerging in drug discovery research combines computational screening of virtual combinatorial libraries against a therapeutic target and targeted combinatorial library synthesis. This new approach includes positive features from both structure-based design and combinatorial chemistry. It has the potential of producing combinatorial libraries with a high hit rate, and hence accelerates the generation of quality lead compounds. The effectiveness of this novel approach has been shown by the design and synthesis of potent inhibitors for serine and aspartyl proteases.

Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond

Covalent Inhibition in Drug Discovery

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Recent applications of covalent chemistries in protein-protein interaction inhibitors

Advances in covalent drug discovery

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

Applications of covalent chemistry in targeted protein degradation

Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action

Advanced technologies for screening and identifying covalent inhibitors

CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

CovalentInDB 2.0: an Updated Comprehensive Database for Structure-Based and Ligand-Based Covalent Inhibitor Design and Screening.

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery

Covalent Inhibitors: To Infinity and Beyond

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

Covalent inhibitors meet epigenetics: New opportunities

Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry